Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2016

Pharma News, 2016

Amgen, Allergan biosimilar found as effective as Roche cancer drug
Amgen, Allergan biosimilar found as effective as Roche cancer drug
Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.
Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
LOS ANGELES, CA, USA - July 22, 2016 - Puma Biotechnology, Inc.
Galenica to Buy Relypsa for $1.53 Billion to Beef Up in U.S
Galenica to Buy Relypsa for $1.53 Billion to Beef Up in U.S
Galenica AG, the owner of Switzerland’s biggest pharmacy network, agreed to buy Relypsa Inc.
Merck KGaA: The German company is building a $115 million life science campus in Burlington, Mass.
Merck KGaA: The German company is building a $115 million life science campus in Burlington, Mass.
Boston—Global technology company Merck KGaA, of Darmstadt, Germany, will build a new 30-acre campus near Routes 3 and 128 in Burlington, Mass.
ApeX Therapeutics Announces FDA Acceptance of IND to Evaluate the Tolerability and Anti-Tumor Effects of APX3330
ApeX Therapeutics Announces FDA Acceptance of IND to Evaluate the Tolerability and Anti-Tumor Effects of APX3330
INDIANAPOLIS, IN, USA I July 20, 2016 - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, today announced the acceptance of an Investigational New Drug ...
Eisai and Arena Pharmaceuticals receive regulatory approval of VENESPRI in Mexico
Eisai and Arena Pharmaceuticals receive regulatory approval of VENESPRI in Mexico
Eisai Inc.
Sanofi offers EU concessions over Boehringer consumer healthcare deal
Sanofi offers EU concessions over Boehringer consumer healthcare deal
BRUSSELS - French drugmaker Sanofi (SASY.
Allergan and Adamas Announce New Expanded Indication for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
Allergan and Adamas Announce New Expanded Indication for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
memantine hydrochloride                 donepezil hydrochloride      DUBLIN, Ireland - July 19, 2016 - Allergan plc (NYSE.
U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults
U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults
empagliflozin                                       metformin hydrochlorideRIDGEFIELD, CT, and INDIANAPOLIS, IN, USA - July 19, 2016 - The U.
Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets
Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets
WOODCLIFF LAKE, NJ and SAN DIEGO, CA, USA - July 19, 2016 - Eisai Inc.
Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
SOLANA BEACH, CA, USA I July 18, 2016 - Evoke Pharma, Inc.
New compounds defeat multi-drug resistant cancer cells
New compounds defeat multi-drug resistant cancer cells
Many cancer deaths occur because cancer cells develop resistance to chemotherapy drugs, prompting a field of research bent on overcoming this treatment barrier.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand